DES versus Bare in primary angioplasty at five years. Initial advantage is reducing

Original: title Long-Term Outcome After Drug-Eluting VersusBare-Metal Stent Implantation in Patients WithST-Segment Elevation Myocardial Infarction. 5 Years Follow-Up From the Randomized DEDICATION (Drug Elution and DistalProtection in Acute Myocardial Infarction) Trial. Reference: Lene Holmvang et al. J Am CollCardiolIntv 2013, article in press.   Primary angioplasty reduced mortality and reinfarction compared with thrombolytics in patients experiencing an ST<a href="https://solaci.org/en/2013/07/05/des-versus-bare-in-primary-angioplasty-at-five-years-initial-advantage-is-reducing/" title="Read more" >...</a>

Double DES in bifurcations, double thrombosis risk

Original title: Late Thrombosis After Double Versus Single Drug-Eluting Stent in the Treatment of Coronary Bifurcations A Meta-analysis of Randomized and Observational Studies. Reference: Marco Zimarino et al. J Am Coll Cardiol Intv 2013. Article in press. In the era of drug-eluting stents, (DES), several randomized and observational studies have been conducted trying to find the best strategy<a href="https://solaci.org/en/2013/06/14/double-des-in-bifurcations-double-thrombosis-risk/" title="Read more" >...</a>

First results of bioabsorbable metal scaffolds DREAMS

Original title: Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial. Reference: Michael Haude et al. Lancet 2013; 381: 836–44. Bioabsorbable scaffolds could improve vasomotion, remodelling and facilitate new interventions, both percutaneous and surgical. This new bioabsorbable scaffold, different from the<a href="https://solaci.org/en/2013/04/18/first-results-of-bioabsorbable-metal-scaffolds-dreams/" title="Read more" >...</a>

IVUS improves outcomes in long lesions with DES

Original title: Randomized Comparison of Clinical Outcomes between Intravascular Ultrasound and Angiography-Guided Drug-Eluting Stent Implantation for Long Coronary Artery Stenosis. Reference: Jung-Sun Kim et al. J Am Coll Cardiol Intv 2013. Article in press. Treating long lesions is difficult and the chance of instant thrombosis may be higher in these lesions. Coronary intravascular ultrasound (IVUS) can help in<a href="https://solaci.org/en/2013/04/11/ivus-improves-outcomes-in-long-lesions-with-des/" title="Read more" >...</a>

The largest series of femoropopliteal in-stent restenosis to date

Original title: Treatment of Femoropopliteal In-Stent Restenosis With Paclitaxel-Eluting Stents. Zilver PTX Global Registry. ZILVER-PTX. Reference: Thomas Zeller et al. J Am Coll Cardiol Intv 2013;6:274–81. Femoropopliteal in-stent restenosis (ISR) is reported in between 19% and 37% of lesions a year and this incidence increases with lesion length.  The ZILVER-PTX study tested the self-expanding paclitaxel-eluting nitinol stent (Cook<a href="https://solaci.org/en/2013/04/08/the-largest-series-of-femoropopliteal-in-stent-restenosis-to-date/" title="Read more" >...</a>

Rotational atherectomy is only an interim strategy.

Original title: High-Speed Rotational Atherectomy Before Paclitaxel-Eluting Stent Implantation in Complex Calcified Coronary Lesions. The Randomized ROTAXUS (Rotational Atherectomy Prior to Taxus Stent Treatment for Complex Native Coronary Artery Disease) Trial. Reference: Mohamed Abdel-Wahab et al. J Am Coll Cardiol Intv 2013; article in press Heavily calcified lesions are difficult and may prevent the appropriate expansion of a<a href="https://solaci.org/en/2013/01/04/rotational-atherectomy-is-only-an-interim-strategy/" title="Read more" >...</a>

Strategies for treating left coronary trunk restenosis.

Original title: Clinical and Procedural Predictors of Suboptimal Outcome After the Treatment of Drug-Eluting Stent Restenosis in the Unprotected Distal Left Main Stem The Milan and New-Tokyo (MITO) Registry. Reference: Circ Cardiovasc Interv. 2012;5: 491-498 We have very little data on the percutaneous treatment of restenosis of an unprotected LMCA.  The aim of this study was to evaluate<a href="https://solaci.org/en/2012/12/06/strategies-for-treating-left-coronary-trunk-restenosis/" title="Read more" >...</a>

Risk score of thrombosis in patients with acute coronary syndrome

Original title: Development and Validation of a Stent Thrombosis Risk Score in Patients With Acute Coronary Syndromes. Reference: George D. Dangas et al. J Am Coll Cardiol Intv 2012;5:1097–105. The implantation of a stent in a pro thrombotic condition such as acute coronary syndrome (ACS) is associated with a higher incidence of stent thrombosis.  There is no data<a href="https://solaci.org/en/2012/11/23/risk-score-of-thrombosis-in-patients-with-acute-coronary-syndrome/" title="Read more" >...</a>

Clinical Significance of Collaterals in Chronic Total Occlusions

Again in the bifurcation, less is more.

It has been reported that the two stents technique is not superior to a provisional stent when treating bifurcations. However, the optimal approach to rescue a secondary branch (SB) when initially opting for provisional stenting has not been established.   The aim of this study was to determine angioplasty indication using balloon or stent for<a href="https://solaci.org/en/2012/11/20/again-in-the-bifurcation-less-is-more/" title="Read more" >...</a>

The use of a paclitaxel eluting balloon in small vessels

Original title: A Randomized Multicenter Study Comparing a Paclitaxel Drug-Eluting Balloon With a Paclitaxel-Eluting Stent in Small Coronary Vessels. The BELLO (Balloon Elution and Late Loss Optimization) Study Reference: Referencia: Azeem Latib et al J Am Coll Cardiol 2012;()doi:10.1016/j.jacc.2012.09.020 The utility of paclitaxel-eluting balloons to treat in-stent restenosis is known but data for novo lesions is more limited. <a href="https://solaci.org/en/2012/11/16/the-use-of-a-paclitaxel-eluting-balloon-in-small-vessels/" title="Read more" >...</a>